Top Markets
Coin of the day
SQZ Biotechnologies Company SQZ Biotechnologies Company

SQZ Biotechnologies Company

SQZ
株式のランク #38920
SQZ Biotechnologies, a biotechnology firm currently in the clinical development... SQZ Biotechnologies, a biotechnology firm currently in the clinical development phase, is focused on creating cell-based therapies for various severe ailments, including cancerous growths, autoimmune disorders, and infectious diseases. Its primary experimental therapeutic, known as SQZ-PBMC-HPV, is derived from its SQZ Antigen Presenting Cells technology. This treatment is currently undergoing Phase I clinical trials, both as a standalone therapy and alongside other immune-oncology treatments, to address advanced or metastatic solid tumors positive for HPV16, encompassing cancers of the cervix, head-and-neck, anus, penis, vulva, and vagina. Furthermore, the company is progressing with SQZ-AAC-HPV, another Phase I clinical candidate targeting the same HPV16+ advanced or metastatic solid tumors, which is also being evaluated as a single agent and in conjunction with other immune-modulating agents. Beyond these, SQZ Biotechnologies is also advancing its SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers platforms. Established in 2013, the company operates from its main office in Watertown, Massachusetts.
株価
$0.05083
最終同期: 2023-09-01
時価総額
$732.57K
変化(1日)
8.15%
変化(1年)
0.00%
US
取引 SQZ Biotechnologies Company (SQZ)

カテゴリー

SQZ Biotechnologies Company(SQZ)の営業利益率
2026 時点の営業利益率 TTM: 0.00%
SQZ Biotechnologies Company の最新の財務報告と株価によると、現在の営業利益率(TTM)は 0.00% です。2026 年末時点では 0.00% でした。
SQZ Biotechnologies Company の営業利益率の履歴(2026 から 2026)
各年末の営業利益率
営業利益率 変化
提供された日付のデータは十分ではありません。
同業他社の営業利益率
企業 営業利益率 営業利益率の差
38.97% -
US
28.81% -
NL
0.00% -
CH
0.00% -
KR
31.23% -
BE
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。